US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,371.93

+19.671.45%

Number of Gainers:12

Number of Losers:7

Number of Flat:1

PE:- -

High:1,374.85

Open:1,352.30

Low:1,342.81

Close:1,352.26

Loading ...

Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying

Pfizer Declares Second-Quarter 2025 Dividend

THOMSON REUTERS

Pfizer - Quarterly Cash Dividend of $0.43 per Share

THOMSON REUTERS

Press Release: Pfizer Declares Second-Quarter 2025 Dividend

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Novavax Shares Surge 17% as FDA Requests Postmarketing Data for COVID-19 Vaccine

Pfizer to have two oral presentations featured in ASCO pre-meeting briefing

Pfizer Advances Bold Vision for Future of Cancer Care at the Asco 2025 Annual Meeting

THOMSON REUTERS

Why vaccine makers aren't worried about Trump administration cuts

Boston Scientific lifts profit view as robust demand expected to shield tariff impact

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Novavax Shares up 15% After Co Says Covid-19 Vaccine Is Approvable Based on Conversations With the US FDA

THOMSON REUTERS

Moderna : TD Cowen Cuts Target Price to $30 From $35

THOMSON REUTERS

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

ACCESS Newswire

3 of Wall Street’s Favorite Stocks Walking a Fine Line

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

AstraZeneca CEO Urges Europe to Spend More on Health or Risk Falling Behind -- Market Talk

Novavax Says COVID Vaccine Application 'Approvable'

MT Newswires Live

FDA Asks Novavax for Commitment on Post-Approval Studies for COVID Vaccine

BUZZ-Novavax rises after saying its COVID-19 vaccine 'approvable' based on FDA talks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1371.928,"timestamp":1745951888778,"preClose":1352.2611,"halted":0,"volume":105041073,"delay":0,"changeRate":0.014544,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":19.66687,"latestTime":"04-29 14:38:08 EDT","open":1352.2991,"high":1374.8529,"low":1342.8104,"amount":3154677394.805445,"amplitude":0.023695,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.606724,"peRate":21.80267,"turnoverRate":0.006773,"increases":12,"decrements":7,"flats":1,"marketCap":1133042476625,"floatMarketCap":1113120946773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1374.8529,"amplitude":0.023695,"preClose":1352.2611,"low":1342.8104,"pbRate":"3.606724","latestPrice":1371.928,"volume":105041073,"delay":0,"open":1352.2991,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1350.4775,"twentyDayClose":1427.887,"sixtyDayClose":1356.0358,"secType":"PLATE","market":"US","turnoverRate":0.006773,"peRate":21.80267,"marketCap":1133042476625,"floatMarketCap":1113120946773,"timestamp":1745951888778,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":12,"down":7,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529336618","title":"Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2529336618","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529336618?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:48","pubTimestamp":1745455715,"startTime":"0","endTime":"0","summary":"We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Viking Therapeutics, Inc.  stands against other takeover rumor stocks hedge funds are buying.Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market. And what more could ignite such a frenzy of activity other than whispers of potential takeovers?When combined with subtle market signals and insider movements, these rumors can cause investors to purchase the stock. Income-seeking investors usually keep a close eye on such signs and movements to capitalize on emerging opportunities.READ ALSO:10 Dividend Paying Stocks Insiders Are Buying. In particular, hedge fund managers, using their vast resources and analytical capabilities, are more receptive to such speculative cues and act upon them. Since investors and the rest of the market tend to generate income by closely following their actions, hedge funds hold influen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viking-therapeutics-inc-vktx-among-004835769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","QLD","LU1057294990.SGD","LU0985481810.HKD","LU0058720904.USD","NVIW.SI","USJW.SI","LU0868494617.USD","MNQmain","VKTX","SG9999001176.SGD","BK4592","BK4534","LU1894683264.USD","BK4568","NQmain","LU0321505868.SGD","BK4588","BK4007","IE00B19Z3581.USD","SG9999002232.USD","LU0234572021.USD","TQQQ","BK4599","IE00BBT3K403.USD","LU1894683348.USD","LU0170899867.USD","SG9999001176.USD","IE000M9KFDE8.USD","SG9999002224.SGD","BK4581","BK4585","IE00BLSP4452.SGD","BK4533","LU0306807586.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU0225284248.USD","LU1023059063.AUD","TSYW.SI","QID","LU0306806265.USD","USAW.SI","LU0122379950.USD","LU0456855351.SGD","PSQ","SG9999003800.SGD",".IXIC"],"gpt_icon":1},{"id":"2529663917","title":"Pfizer Declares Second-Quarter 2025 Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2529663917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529663917?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:40","pubTimestamp":1745440800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA3MNWBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0456855351.SGD","LU0985481810.HKD","BK4007","SG9999013999.USD","IE00BLSP4239.USD","BK4581","LU0234572021.USD","LU1894683348.USD","BK4592","SG9999011175.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","LU0170899867.USD","IE00B19Z3581.USD","LU0225284248.USD","LU0321505439.SGD","SG9999002224.SGD","LU0321505868.SGD","LU1066051498.USD","LU1023059063.AUD","BK4533","SG9999001176.USD","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0289739699.SGD","LU0868494617.USD","PFE","LU0058720904.USD","IE0002270589.USD","LU0306807586.USD","BK4588","LU0225771236.USD","BK4568","IE000M9KFDE8.USD","SG9999001176.SGD","BK4550","BK4599","LU1066053197.SGD","SG9999002232.USD","LU0122379950.USD","LU1883839398.USD","LU1057294990.SGD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2529663468","title":"Pfizer - Quarterly Cash Dividend of $0.43 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2529663468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529663468?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:40","pubTimestamp":1745440800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA3MNWBD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","LU0306806265.USD","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4588","LU1023059063.AUD","PFE","BK4592","SG9999001176.SGD","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","IE0002270589.USD","BK4533","LU0122379950.USD","IE00B19Z3B42.SGD","SG9999001176.USD","SG9999002224.SGD","LU1057294990.SGD","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD","BK4581"],"gpt_icon":0},{"id":"2529663458","title":"Press Release: Pfizer Declares Second-Quarter 2025 Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2529663458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529663458?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:40","pubTimestamp":1745440800,"startTime":"0","endTime":"0","summary":"Board of Directors approves quarterly cash dividend of $0.43 per share. Pfizer Inc.  today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","LU0234572021.USD","LU1066051498.USD","LU0225284248.USD","LU0456855351.SGD","IE00BLSP4452.SGD","BK4592","LU0170899867.USD","SG9999003800.SGD","SG9999001176.SGD","LU1057294990.SGD","LU1894683348.USD","LU0058720904.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","BK4599","IE0002270589.USD","LU1066053197.SGD","LU0306807586.USD","SG9999002224.SGD","SG9999001176.USD","SG9999011175.SGD","IE00B19Z3581.USD","BK4533","BK4550","PFE","SG9999013999.USD","BK4007","LU1894683264.USD","LU0122379950.USD","LU0306806265.USD","BK4534","LU1883839398.USD","LU0289739699.SGD","LU0868494617.USD","LU0321505439.SGD","LU0321505868.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","BK4585","BK4581","LU0225771236.USD","BK4588","LU0985481810.HKD","BK4568","SG9999002232.USD"],"gpt_icon":1},{"id":"2529668948","title":"Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668948","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668948?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:08","pubTimestamp":1745438880,"startTime":"0","endTime":"0","summary":"Data from Cohorts 1-3 of trial to be presented in an oral session and poster at theSociety for Investigative Dermatology  2025 Annual Meeting. Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025. SOUTH SAN FRANCISCO, Calif., April 23, 2025  -- Corvus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting, which is taking place May 7-10, 2025 in San Diego, CA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corvus-pharmaceuticals-present-interim-data-200800399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","SID","CRVS","BK4568","BK4139"],"gpt_icon":0},{"id":"2529668166","title":"Novavax Shares Surge 17% as FDA Requests Postmarketing Data for COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668166","media":"GuruFocus.com","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668166?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:04","pubTimestamp":1745438697,"startTime":"0","endTime":"0","summary":"Novavax  shares jumped 17.1% to $7.32 as of 1:10 p.m. ET on Wednesday after the company said it received a request from the U.S. Food and Drug Administration for additional postmarketing clinical data related to its COVID-19 vaccine license application.GuruFocus has detected 3 Warning Signs with NVAX.The company said the FDA issued a formal information request tied to its Biologics License Application  and asked for a postmarketing commitment. Novavax said it aims to respond promptly to move the vaccine closer to full regulatory approval.The request comes after the April 1 Prescription Drug User Fee Act deadline, during which Novavax said it had constructive discussions with the agency.Novavax stated that while it believes its application is approvable, final approval remains contingent on meeting the FDA's requirements.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novavax-shares-surge-17-fda-200457518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4588","BK4547","NVAX","BK4568","BNTX","BK4535","BK4551","BK4139","BK4585"],"gpt_icon":0},{"id":"2529965772","title":"Pfizer to have two oral presentations featured in ASCO pre-meeting briefing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529965772","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529965772?lang=en_us&edition=fundamental","pubTime":"2025-04-24 03:50","pubTimestamp":1745437817,"startTime":"0","endTime":"0","summary":"The company states: “Pfizer (PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pfizer-to-have-two-oral-presentations-featured-in-asco-pre-meeting-briefing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pfizer-to-have-two-oral-presentations-featured-in-asco-pre-meeting-briefing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1894683348.USD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU0306806265.USD","LU0321505439.SGD","LU1057294990.SGD","LU1066051498.USD","LU0225284248.USD","BK4599","LU0321505868.SGD","BK4568","LU1066053197.SGD","LU1894683264.USD","PFE","SG9999013999.USD","LU0170899867.USD","BK4581","IE00BBT3K403.USD","LU0122379950.USD","LU0234572021.USD","BK4550","BK4534","BK4592","SG9999002232.USD","LU0868494617.USD","LU1883839398.USD","BK4533","SG9999003800.SGD","LU0289739699.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0058720904.USD","BK4585","LU0306807586.USD","SG9999001176.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU1023059063.AUD","LU0225771236.USD","BK4007","BK4588","SG9999002224.SGD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2529576246","title":"Pfizer Advances Bold Vision for Future of Cancer Care at the Asco 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529576246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529576246?lang=en_us&edition=fundamental","pubTime":"2025-04-24 03:46","pubTimestamp":1745437560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA82G5GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4588","LU0122379950.USD","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","LU1023059063.AUD","LU0058720904.USD","BK4592","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2529748654","title":"Why vaccine makers aren't worried about Trump administration cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2529748654","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529748654?lang=en_us&edition=fundamental","pubTime":"2025-04-24 02:50","pubTimestamp":1745434227,"startTime":"0","endTime":"0","summary":"Large and mid-cap vaccine makers are, as of now, unworried about their 2025 pipelines in the face of research funding declines by the Trump administration and a drop in biotech funding.That's what some of the top vaccine-maker executives told Yahoo Finance this week at the World Vaccine Congress in Washington, D.C.These executives believe there will be no impact from the funding cuts and policies coming down from the Trump administration, while others view it as a four-year storm they will just have to weather before being able to carry on as usual afterward.\"We're in this for the long game. We believe in vaccines, in the value of vaccines, and what they bring to public health. Infectious diseases aren't going to go away, so the need for vaccines is going to remain long-term,\" said Sally Mossman, head of research portfolio strategy at Sanofi .It's no wonder since vaccines make up a good chunk of revenue, even for large-cap pharmaceuticals with diversified portfolios. Among the companie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-vaccine-makers-arent-worried-about-trump-administration-cuts-185027024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","SG9999014567.USD","LU1066051498.USD","LU1989772840.SGD","LU1069347547.HKD","LU1035773651.USD","LU2361044865.SGD","IE00BLSP4452.SGD","LU0321505868.SGD","SG9999002232.USD","BK4534","LU2361044949.HKD","BK4568","LU1934455863.HKD","BK4581","SGXZ57979304.SGD","IE0002270589.USD","BK4533","MRNA","PFE","IE00BJJMRZ35.SGD","LU0965508806.USD","LU1883839398.USD","LU2468319806.SGD","LU2023250843.SGD","LU1061106388.HKD","MRK","LU1116320737.USD","LU0861579265.USD","LU0265550359.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0203345920.USD","LU0058720904.USD","LU1066053197.SGD","GSK","LU0211331839.USD","LU1037948897.HKD","LU0985481810.HKD","LU1057294990.SGD","LU1093756168.USD","LU1934455277.USD","LU0106261372.USD","BK4599","SG9999001176.USD","LU2361045086.USD","IE0009355771.USD","BK4550","GSK.UK","LU1430594728.SGD"],"gpt_icon":1},{"id":"2529639168","title":"Boston Scientific lifts profit view as robust demand expected to shield tariff impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2529639168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529639168?lang=en_us&edition=fundamental","pubTime":"2025-04-23 23:18","pubTimestamp":1745421505,"startTime":"0","endTime":"0","summary":"UPDATE 1-Boston Scientific lifts profit view as robust demand expected to shield tariff impact Adds company comments on tariffs throughout, updates sharesBy Mariam Sunny and Padmanabhan Ananthan. April 23  - Boston Scientific BSX.N raised its annual profit forecast and said strong demand for its medical devices would buffer a potential $200 million tariff-related hit, sending its shares up nearly 6% on Wednesday.The upbeat outlook comes against the backdrop of expectation that demand for non-urgent procedures will remain elevated this year, a trend highlighted by health insurance giant UnitedHealth Group UNH.N last week.The medtech firm expects this trend to shield it from U.S. President Donald Trump's levies, which have been particularly aggressive on China, a critical supplier of raw materials and components for the pharmaceutical and medical device industries.\"Our ability to absorb the tariffs I think is more unique than most companies given the strength of the growth,\" CEO Mike Mah","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R119P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1720051017.SGD","IE00B1BXHZ80.USD","LU1323610961.USD","IE0002270589.USD","BK4568","LU1989763690.USD","SG9999014898.SGD","LU0345770308.USD","LU0098860793.USD","LU1720051108.HKD","SGXZ81514606.USD","LU0640476718.USD","LU0985320562.USD","LU2491050154.USD","LU0234572021.USD","IE00BN8TJ469.HKD","LU0225283273.USD","IE000M9KFDE8.USD","BSX","LU1064131342.USD","IE0005OL40V9.USD","LU1674673428.USD","LU1674673691.USD","LU2362541513.USD","LU1267930573.SGD","IE00B19Z8X17.USD","IE00BJJMRY28.SGD","LU2468319806.SGD","LU2430703251.USD","LU0267386448.USD","LU0683600562.USD","JNJ","LU2361044949.HKD","LU2125154935.USD","LU0052756011.USD","LU0792757196.USD","LU2265009873.SGD","LU0289739699.SGD","LU0553294199.USD","LU1935042991.SGD","LU1791710400.SGD","LU1989763427.SGD","LU1057294990.SGD","LU0912757837.SGD","SG9999014906.USD","ABT","LU2357305700.SGD","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2529639089","title":"Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529639089","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529639089?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:44","pubTimestamp":1745419440,"startTime":"0","endTime":"0","summary":"– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial –。NEW HAVEN, Conn., April 23, 2025  -- Arvinas, Inc.  today announced that data from the global Phase 3 VERITAC-2 clinical trial  evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative  advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology  Annual Meeting, taking place May 30 – June 3 in Chicago, IL. The presentation includes the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera  estrogen receptor  degrader.About ArvinasArvinas  is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, the Company is pioneer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arvinas-announces-results-veritac-2-144400849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999013999.USD","LU1894683264.USD","LU0225771236.USD","LU0321505868.SGD","IE0002270589.USD","IE000M9KFDE8.USD","BK4592","IE00BLSP4452.SGD","LU0058720904.USD","AFG","SG9999002224.SGD","SG9999002232.USD","LU0289739699.SGD","LU1023059063.AUD","LU1883839398.USD","IE00BLSP4239.USD","BK4568","LU0306806265.USD","LU1066051498.USD","SG9999003800.SGD","SG9999001176.SGD","LU0225284248.USD","LU0122379950.USD","BK4550","LU1057294990.SGD","LU0868494617.USD","BK4534","IE00B19Z3581.USD","BK4117","LU1894683348.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","BK4585","LU0321505439.SGD","LU0234572021.USD","SG9999011175.SGD","ARVN","BK4533","BK4007","BK4599","BK4107","BK4588","LU0306807586.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1066053197.SGD","LU0985481810.HKD","LU0170899867.USD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2529686732","title":"Novavax Shares up 15% After Co Says Covid-19 Vaccine Is Approvable Based on Conversations With the US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2529686732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529686732?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:31","pubTimestamp":1745415075,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R119S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4568","BK4547","BK4588","BK4139","NVAX"],"gpt_icon":0},{"id":"2529686373","title":"Moderna : TD Cowen Cuts Target Price to $30 From $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2529686373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529686373?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:24","pubTimestamp":1745414694,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R119Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4533","BK4568","BK4532","BK4139","BK4501","BK4551","BK4585","MRNA","BK4548","BK4588"],"gpt_icon":0},{"id":"2529868706","title":"Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2529868706","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529868706?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:10","pubTimestamp":1745413800,"startTime":"0","endTime":"0","summary":"Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry. Lexaria's technology could enhance performance and lower side effects. By enhancing the performance of oral dosing choices as a replacement for disliked injections; and by reducing adverse events - often the #1 reason that patients stop using GLP-1 drugs - Lexaria's proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drug.Eli Lilly plans to apply for approval to launch the drug for both weight loss and diabetes treatment in 2026 - and that rapid path to market, combined with the fact that it might be only the 2nd oral GLP-1 drug to potentially be approved by the Food and Drug Administration , is likely responsible for the dramatic market response to the news.Although clearly a positive step forward for the weight loss and diabetes treatment sectors, it should still be noted that 13% to 18% of patients receiving the drug ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recent-glp-1-industry-developments-131000677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","LU0122379950.USD","LU1066053197.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU1057294990.SGD","SG9999013999.USD","BK4533","BK4581","IE00B19Z3B42.SGD","SG9999001176.SGD","BK4144","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","LU1894683348.USD","IE0002270589.USD","BK4007","GLP","LU1066051498.USD","LU1894683264.USD","BK4599","SG9999003800.SGD","LU0225771236.USD","LU1883839398.USD","LU0321505439.SGD","IE000M9KFDE8.USD","BK4534","LU0225284248.USD","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4590","BK4592","LU0306806265.USD","IE00B19Z3581.USD","LEXXW","LU0306807586.USD","IE00BLSP4239.USD","BK4550","SG9999001176.USD","LEXX","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2529682525","title":"3 of Wall Street’s Favorite Stocks Walking a Fine Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2529682525","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529682525?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:04","pubTimestamp":1745413440,"startTime":"0","endTime":"0","summary":"Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.Specializing in digital casino gaming, Inspired  is a provider of gaming hardware, virtual sports platforms, and server-based gaming systems.Annual revenue growth of 3.1% over the last two years was below our standards for the consumer discretionary sector. Anticipated sales growth of 2.2% for the next year implies demand will be shaky. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital. Pfizer ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-wall-street-favorite-stocks-130400724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BBT3K403.USD","IE00B19Z3581.USD","LU0225771236.USD","LU0321505439.SGD","SG9999002232.USD","BK4568","BK4581","BK4216","BK4007","LU1894683264.USD","LU0122379950.USD","LU1883839398.USD","SG9999001176.USD","LU0306807586.USD","SG9999001176.SGD","INSE","SGXZ57979304.SGD","BK4534","BK4588","LU0234572021.USD","PFE","BK4550","LU0170899867.USD","SG9999003800.SGD","LU0058720904.USD","LU0289739699.SGD","SG9999013999.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","BK4585","SG9999011175.SGD","LU0306806265.USD","LU1066051498.USD","LU1894683348.USD","LU0321505868.SGD","LU0225284248.USD","LU1066053197.SGD","IE00BLSP4239.USD","IE0002270589.USD","SG9999002224.SGD","LU0868494617.USD","BK4599","MTN","LU0456855351.SGD","LU0985481810.HKD","LU1057294990.SGD","BK4150","IE00BLSP4452.SGD","BK4592"],"gpt_icon":1},{"id":"2529625636","title":"GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529625636","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529625636?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:00","pubTimestamp":1745413200,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - April 23, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-report-first-quarter-2025-130000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4568","BK4535","R","BK4139","BNTX","BK4022","BK4588","GOVX","BK4232","BK4585","GOVXW","BK4548","BK4551"],"gpt_icon":0},{"id":"2529268811","title":"AstraZeneca CEO Urges Europe to Spend More on Health or Risk Falling Behind -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2529268811","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529268811?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:57","pubTimestamp":1745413020,"startTime":"0","endTime":"0","summary":"1256 GMT - AstraZeneca's Chief Executive officer Pascal Soriot says Europe must boost investment into healthcare, as it has done with defense spending, amid what he calls a shifting world order. \"Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk,\" Soriot says. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2462157665.USD","LU2456880835.USD","SNY","LU0070302665.USD","IE0002141913.USD","BK4578","BK4568","LU2417539215.USD","LU0889565916.HKD","NVS","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","BK4532","IE0009355771.USD","IE00BFXG1179.USD","LU1829250122.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0320765489.SGD","LU0208291251.USD","LU0109394709.USD","BK4007","BK4588","AZN","LU2236285917.USD"],"gpt_icon":0},{"id":"2529688883","title":"Novavax Says COVID Vaccine Application 'Approvable'","url":"https://stock-news.laohu8.com/highlight/detail?id=2529688883","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529688883?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:45","pubTimestamp":1745412308,"startTime":"0","endTime":"0","summary":"Novavax  said Wednesday it believes its biologics license application for its COVID-19 vaccine is \"approvable\" by the US Food and Drug Administration based on ongoing discussions.The company said the FDA recently asked for a post-marketing commitment to collect additional clinical data.Novavax said it will work quickly to comply with the request and obtain final approval.Shares of Novavax rose 12% in recent premarket activity Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4547","BK4585","BK4568","NVAX","BK4588"],"gpt_icon":0},{"id":"2529050762","title":"FDA Asks Novavax for Commitment on Post-Approval Studies for COVID Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2529050762","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529050762?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:33","pubTimestamp":1745411602,"startTime":"0","endTime":"0","summary":"UPDATE 1-FDA asks Novavax for commitment on post-approval studies for COVID vaccineAdds shares in paragraph 2, details in paragraphs 3,4 and 5April 23  - Novavax NVAX.O said on Wednesday the U.S. Food and Drug Administration has sought a commitment from the COVID-19 vaccine maker for additional clinical data if it approves the shot.Shares of the biotech rose 12% to $7.07 in premarket trading. The FDA had missed its deadline for making a decision on traditional approval for the company's protein-based shot earlier this month. Novavax said it believes that the company's marketing application is \"approvable\" based on its conversations with the FDA.   ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R117S:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","BK4547","BK4568","NVAX"],"gpt_icon":1},{"id":"2529077995","title":"BUZZ-Novavax rises after saying its COVID-19 vaccine 'approvable' based on FDA talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2529077995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529077995?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:28","pubTimestamp":1745411295,"startTime":"0","endTime":"0","summary":"BUZZ-Novavax rises after saying its COVID-19 vaccine 'approvable' based on FDA talks**  Shares of vaccine maker Novavax NVAX.O rise  13% to $7.06 premarket** Co says its COVID-19 vaccine is \"approvable based on conversations with the U.S. Food and Drug Administration \"** NVAX also says it has received a request from the FDA for a commitment to provide additional clinical data on its vaccine if it secures an approval**  The FDA had missed its deadline for making a decision on traditional approval for co's protein-based shot earlier this month** Up to last close, stock had fallen 22.3% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL6N3R10JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4568","BK4547","NVAX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":9,"totalSize":306,"code":"91000000","status":"200"}]}}